Table 1 Baseline clinical and procedure characteristics of patients according to ejection fraction
Baseline clinical characteristics | Total population (n = 650) | LVEF < 50% (n = 261) | LVEF ≥ 50% (n = 389) | P value |
|---|---|---|---|---|
Age, years | 61.63 ± 10.57 | 62.08 ± 10.66 | 61.32 ± 10.51 | 0.418 |
Sex, male, n (%) | 502 (77.2) | 217 (83.1) | 285 (73.3) | 0.003 |
BMI, kg/m2 | 25.28 ± 3.19 | 25.19 ± 3.35 | 25.35 ± 3.04 | 0.427 |
Heart rate, bpm | 74 (66–83) | 78 (68–89) | 72 (66–80) | < 0.001 |
SBP, mmHg | 129.93 ± 19.75 | 125.21 ± 20.77 | 133.10 ± 18.39 | < 0.001 |
DBP, mmHg | 79.79 ± 13.18 | 79.96 ± 14.58 | 79.68 ± 12.17 | 0.940 |
Smoking, n (%) | 350 (53.8) | 166 (63.6) | 184 (47.3) | < 0.001 |
Drinking, n (%) | 126 (19.4) | 47 (18.0) | 79 (20.3) | 0.467 |
Hypertension, n (%) | 359 (55.2) | 121 (46.4) | 238 (61.2) | < 0.001 |
Family history of CAD, n (%) | 71 (10.9) | 22 (8.4) | 49 (12.6) | 0.095 |
NT-proBNP, pg/mL | 281.2 (92.2–1069.0) | 1075.5 (351.0–2840.0) | 132.5 (56.14–367.05) | < 0.001 |
Cardiac troponin T, ng/mL | 0.305 (0.009–0.492) | 0.418 (0.044–1.575) | 0.110 (0.007–0.049) | < 0.001 |
Hemoglobin, g/L | 141.48 ± 16.46 | 141.19 ± 17.32 | 141.68 ± 15.88 | 0.778 |
Platelet, 109/L | 205.38 ± 63.37 | 206.43 ± 67.71 | 204.68 ± 60.36 | 0.851 |
White blood cells, 109/L | 7.15 (5.61–9.47) | 8.40 (6.38–10.96) | 6.57 (5.32–8.35) | < 0.001 |
Neutrophils, 109/L | 4.97 (3.66–7.09) | 6.55 (4.34–8.86) | 4.43 (3.40–5.87) | < 0.001 |
Lymphocyte, 109/L | 1.43 (1.07–1.86) | 1.31 (0.98–1.79) | 1.52 (1.15–1.91) | < 0.001 |
Monocytes, 109/L | 0.35 (0.28–0.47) | 0.41 (0.30–0.56) | 0.33 (0.26–0.43) | < 0.001 |
NLR | 3.29 (2.31–5.71) | 4.79 (2.84–7.50) | 2.88 (2.06–4.05) | < 0.001 |
MLR | 0.24 (0.18–0.34) | 0.28 (0.22–0.42) | 0.21 (0.16–0.29) | < 0.001 |
PLR | 136.47 (104.06–185.04) | 149.31 (110.22–203.71) | 129.82 (97.81–169.92) | < 0.001 |
hs-CRP, mg/L | 1.90 (0.77–5.40) | 3.59 (1.54–10.00) | 1.145 (0.54–3.07) | < 0.001 |
ALT, U/L | 27 (18–40) | 30 (21–47) | 23 (16–35) | < 0.001 |
AST, U/L | 26 (20–56) | 47 (26–116) | 22 (18–31) | < 0.001 |
Albumin, g/L | 40.54 ± 4.65 | 38.86 ± 4.88 | 41.67 ± 4.13 | < 0.001 |
BUN, mmol/L | 5.66 ± 1.78 | 5.77 ± 2.09 | 5.58 ± 1.54 | 0.992 |
Scr, µmol/L | 67.78 ± 19.59 | 70.35 ± 23.19 | 66.05 ± 16.54 | 0.047 |
Cystatin C, mg/L | 1.032 ± 0.326 | 1.079 ± 0.336 | 1.001 ± 0.316 | 0.005 |
FPG, mg/dL | 4.74 (4.20–5.42) | 4.70 (4.27–5.44) | 4.77 (4.20–5.41) | 0.966 |
RBG, mg/dL | 6.23 (5.31–7.68) | 6.23 (5.33–7.65) | 6.23 (5.29–7.71) | 0.776 |
eGFR, mL/(min*1.73 m2) | 96.87 (88.69–104.62) | 95.77 (85.58–104.05) | 97.62 (90.35–105.52) | 0.058 |
K+, mmol/L | 3.93 ± 0.39 | 3.92 ± 0.39 | 3.93 ± 0.40 | 0.629 |
Na+, mmol/L | 141.04 ± 3.39 | 140.24 ± 3.92 | 141.57 ± 2.87 | < 0.001 |
Ca2+, mmol/L | 2.30 ± 0.14 | 2.25 ± 0.14 | 2.33 ± 0.13 | < 0.001 |
Uric acid, µmol/L | 340.25 ± 86.98 | 339.28 ± 91.75 | 340.91 ± 83.73 | 0.763 |
Homocysteine, µmol/L | 17.7 (13.9–23.5) | 20.7 (15.8–33.4) | 15.9 (13.3–20.4) | < 0.001 |
PT, s | 13.4 (13.0–13.8) | 13.7 (13.2–14.1) | 13.3 (12.9–13.7) | < 0.001 |
PTA, % | 90.94 ± 13.64 | 87.83 ± 13.62 | 93.03 ± 13.27 | < 0.001 |
INR | 1.04 (1.00–1.08) | 1.06 (1.02–1.11) | 1.03 (0.99–1.07) | < 0.001 |
APTT, s | 36.4 (33.9–39.4) | 37.7 (34.7–41.4) | 35.9 (33.4–38.3) | < 0.001 |
TT, s | 16.6 (15.8–17.4) | 16.6 (15.7–17.5) | 16.5 (15.9–17.3) | 0.727 |
FIB, g/L | 3.33 (2.84–3.79) | 3.58 (3.12–4.32) | 3.15 (2.69–3.53) | < 0.001 |
d-dimer, mg/L | 0.44 (0.30–0.70) | 0.56 (0.40–0.90) | 0.40 (0.30–0.56) | < 0.001 |
FDP, mg/L | 1.20 (0.90–1.70) | 1.40 (0.96–2.30) | 1.20 (0.90–1.50) | < 0.001 |
Triglycerides, mmol/L | 1.29 (0.97–1.82) | 1.17 (0.83–1.66) | 1.38 (1.04–1.97) | < 0.001 |
TC, mmol/L | 3.74 (3.14–4.42) | 3.77 (3.12–4.46) | 3.73 (3.15–4.38) | 0.638 |
LDL, mmol/L | 2.21 (1.68–2.79) | 2.28 (1.71–2.79) | 2.15 (1.65–2.79) | 0.242 |
HDL, mmol/L | 0.91 (0.78–1.07) | 0.92 (0.78–1.06) | 0.91 (0.77–1.08) | 0.884 |
apoA, g/L | 1.082 (0.967–1.212) | 1.067 (0.918–1.194) | 1.100 (0.995–1.232) | 0.001 |
apoB, g/L | 0.763 (0.627–0.924) | 0.800 (0.627–0.934) | 0.751 (0.622–0.909) | 0.202 |
apoE, g/L | 33.1 (26.5–40.8) | 32.5 (26.7–41.1) | 33.4 (26.3–40.7) | 0.877 |
Lp (a), mg/L | 184 (95–338) | 239 (118–371) | 153 (86–309) | < 0.001 |
LVEF, % | 60 (45–67) | 43 (39–47) | 66 (62–70) | < 0.001 |
FAR | 81.43 (67.66–97.62) | 91.37 (79.38–116.50) | 75.14 (63.76–87.13) | < 0.001 |
Gensini score | 62 (40–90) | 80 (50–100) | 52 (34–80) | < 0.001 |
Initial diagnosis, n (%) | 0.138 | |||
UA | 352 (54.2) | 59 (22.6) | 293 (75.3) | < 0.001 |
NSTEMI | 82 (12.6) | 41 (15.7) | 41 (10.5) | 0.052 |
STEMI | 216 (33.2) | 161 (61.7) | 55 (14.1) | < 0.001 |
Killip class | ||||
I | 285 (43.8) | 165 (63.2) | 120 (30.8) | < 0.001 |
II | 303 (46.6) | 57 (21.8) | 246 (63.2) | < 0.001 |
≥ III | 62 (9.5) | 39 (14.9) | 23 (5.9) | < 0.001 |
Diseased vessels number, n (%) | ||||
One-vessel disease | 146 (12.9) | 142 (13.8) | 4 (3.9) | 0.005 |
Two-vessel disease | 316 (28.0) | 294 (28.6) | 22 (21.6) | 0.131 |
Three-vessel disease | 663 (58.7) | 587 (57.1) | 76 (74.5) | < 0.001 |
Diseased vessels type, n (%) | ||||
LM | 85 (7.5) | 76 (7.4) | 9 (8.8) | 0.601 |
LAD | 1055 (93.4) | 958 (93.2) | 97 (95.1) | 0.460 |
LCX | 845 (74.8) | 770 (74.9) | 75 (73.5) | 0.761 |
RCA | 860 (76.1) | 779 (75.8) | 81 (79.4) | 0.412 |
Target vessel territory, n (%) | ||||
LAD | 742 (65.7) | 677 (65.9) | 65 (63.7) | 0.666 |
LCX | 356 (31.5) | 325 (31.6) | 31 (30.4) | 0.800 |
RCA | 482 (42.7) | 444 (43.2) | 38 (37.3) | 0.248 |
Number of stents, n (%) | ||||
1 | 404 (35.8) | 365 (35.5) | 39 (38.2) | 0.583 |
2 | 341 (30.2) | 320 (31.1) | 21 (20.6) | 0.027 |
≥ 3 | 385 (34.1) | 343 (33.4) | 42 (41.2) | 0.112 |
Average length of stents, mm | 26.79 ± 5.86 | 26.73 ± 5.84 | 27.39 ± 6.08 | 0.321 |
Average width of stents, mm | 2.98 ± 0.43 | 2.98 ± 0.42 | 2.98 ± 0.43 | 0.652 |
Plaque property, n (%) | ||||
Calcification lesions | 142 (21.8) | 45 (17.2) | 97 (24.9) | 0.020 |
Diffuse lesions | 171 (26.3) | 56 (21.5) | 115 (29.6) | 0.021 |
Thrombus | 30 (4.6) | 18 (6.9) | 12 (3.1) | 0.023 |
Chronic total occlusions | 93 (14.3) | 51 (19.5) | 42 (10.8) | 0.002 |